Profil bibliographique

Ingemar Torstensson

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

16Publications signalées

4366Citations signalées

0Affiliations récentes

Domaines associés

Lipoproteins and Cardiovascular HealthVenous Thromboembolism Diagnosis and ManagementAtrial Fibrillation Management and OutcomesDiabetes, Cardiovascular Risks, and LipoproteinsAntiplatelet Therapy and Cardiovascular Diseases

Publications récentes

Accès ouvert 2025 articleOpenAlex

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

Philippe Gabríel Steg, Michael Szarek, J. Wouter Jukema, Deepak L. Bhatt et autres

25 citationsCirculation

Accès ouvert 2024 articleOpenAlex

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

Shaun G. Goodman, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

24 citationsEuropean Heart Journal - Cardiovascular Pharmacotherapy

Accès ouvert 2022 articleOpenAlex

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

125 citationsCirculation

Accès ouvert 2021 articleOpenAlex

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo, Garen Manvelian et autres

144 citationsJournal of the American College of Cardiology

Accès ouvert 2021 articleOpenAlex

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner, Deepak L. Bhatt et autres

40 citationsDiabetes Care

Accès ouvert 2019 articleOpenAlex

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie T. Baccara‐Dinet et autres

331 citationsThe Lancet Diabetes & Endocrinology

Accès ouvert 2018 articleOpenAlex

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, Ralph B. D’Agostino et autres

1840 citationsThe Lancet

Accès ouvert 2017 articleOpenAlex

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Stuart J. Connolly, John W. Eikelboom, Jackie Bosch, Gilles R. Dagenais et autres

757 citationsThe Lancet

Accès ouvert 2017 articleOpenAlex

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Sonia S. Anand, Jackie Bosch, John W. Eikelboom, Stuart J. Connolly et autres

891 citationsThe Lancet

2008 articleOpenAlex

[Questionnaires at anticoagulation clinics in the Southern health care region. A national quality registry is needed].

Ingemar Torstensson, Sten-Erik Bäck

0 citationsPubMed

2004 otherOpenAlex

[D-dimer analysis in diagnosis of venous thromboembolism is reliable].

Ingemar Torstensson, Jesper Persson, Sten-Erik Bäck

1 citationPubMed

1998 articleOpenAlex

Out-patient treatment of acute deep vein thrombosis.

Ingrid Mattiasson, Erik Berntorp, Stig Bornhov, C Lagerstedt et autres

23 citationsPubMed

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.